Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Molecular Medicine
Reference62 articles.
1. Current and emerging therapies for patients with advanced non-small-cell lung cancer;Sheth;Am J Health Syst Pharm,2010
2. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer;Amarasena;Cochrane Database Syst Rev,2008
3. Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer;Carnio;Expert Rev Anticancer Ther,2014
4. Combined targeted therapies in non-small cell lung cancer: a winner strategy?;Cascone;Curr Opin Oncol,2007
5. Hallmarks of cancer: the next generation;Hanahan;Cell,2011
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ionizable Drugs Enable Intracellular Delivery of Co‐Formulated siRNA;Advanced Materials;2024-08-15
2. A patent perspective of antiangiogenic agents;Expert Opinion on Therapeutic Patents;2023-12-02
3. Quinacrine enhances the efficacy of cisplatin by increasing apoptosis and modulating cancer survival proteins in a colorectal cancer cell line;Journal of Cancer Research and Therapeutics;2023
4. Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells;Evidence-Based Complementary and Alternative Medicine;2022-06-24
5. Improvement of Cellular Pattern Organization and Clarity Through Centrifugal Force;SSRN Electronic Journal;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3